Sapan Gai, CCO at Sovereign Metals, discusses their superior graphite test results. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,264.00
Bid: 12,280.00
Ask: 12,282.00
Change: 146.00 (1.20%)
Spread: 2.00 (0.016%)
Open: 12,244.00
High: 12,384.00
Low: 12,228.00
Prev. Close: 12,118.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: Stocks fall but pound up before US data

Tue, 13th Feb 2024 12:06

(Alliance News) - Stock prices in London were on the decline on Tuesday afternoon, with sentiment tetchy ahead of a US inflation report later.

The pound traded higher, meanwhile, on robust labour market data which may encourage some to rethink their dovish Bank of England expectations.

The FTSE 100 index traded 20.66 points lower, 0.3%, at 7,553.03. The FTSE 250 was down 117.64 points, 0.6%, at 19,086.29, though the AIM All-Share edged down 0.14 of a point to 750.04.

The Cboe UK 100 fell 0.3% to 755.04, the Cboe UK 250 dropped 0.6% to 16,516.30, and the Cboe Small Companies was down 0.2% at 14,361.50.

The CAC 40 in Paris and the DAX 40 in Frankfurt were both down 0.5%.

Stocks in New York are called to open lower. The Dow Jones Industrial Average is called down 0.1%, the S&P 500 0.4% lower and the Nasdaq Composite down 0.7%.

"Markets remained in a holding pattern, awaiting the next wave of inflation, manufacturing and GDP data to see if it is possible to second guess when central banks might press the magic 'cut' button on interest rates," AJ Bell analyst Russ Mould commented.

"Stronger than expected labour data from the UK didn't help matters as it effectively gives the Bank of England another reason to keep rates steady and not rush to cut them."

The pound was quoted at USD1.2664 early Tuesday afternoon, up from USD1.2621, where it stood at the time of the London equities close on Monday.

According to the Office for National Statistics, the jobless rate faded to 3.8% in the three months to the end of December from 4.2% in the period from September to November.

Unemployment had been expected to ease slightly less, to 4.0%, according to FXStreet-cited market consensus.

Annual growth in regular earnings, so excluding bonuses, amounted to 6.2% in the three months to December. Including bonuses, earnings rose 5.8% on-year.

Pay growth was hotter than expected by both measures. Earnings including bonuses had been expected to rise by 5.6%, according to FXStreet, while excluding bonuses, a rise of 6.0% was forecast.

The next batch of UK unemployment data is scheduled for March 12, so before the BoE's next decision on March 21.

On Wednesday, the ONS reports UK inflation data for January. Annual consumer price inflation is expected to have picked up to 4.2% last month from 4.0% in December, according to FXStreet.

Analysts at Lloyds Bank commented: "Nevertheless, we expect inflation to resume its downtrend in February and to return to 2% by the spring. BoE policymakers, however, may want to see more evidence of a sustained fall in inflation to target before commencing with rate cuts."

The euro traded at USD1.0775 early Tuesday afternoon, largely flat against USD1.0769 late Monday. Versus the yen, the dollar bought JPY149.41, down slightly from JPY149.44.

The afternoon's main event will be the US inflation data at 1330 GMT. Annual consumer price growth is expected to have ebbed to 2.9% last month, according to FXStreet, from 3.4% in December.

Scope Markets analyst Joshua Mahony commented: "Coming off the back of a period that has seen the Federal Reserve consistently reigning in market expectations over the timing and scope of their 2024 rate cuts, today's expected slide in US CPI could be a short reprieve from that trend. With the 0.5% reading from last January dropping out of the annual metric, base effects should help provide the basis for a welcome decline in inflation today. However, the wider picture remains problematic, with the pathway back to 2% looking far from simple."

In London, property firms were among the worst large-cap performers following the red-hot UK data.

Property portal Rightmove fell 3.0%, while housebuilders Taylor Wimpey and Persimmon fell 2.1% and 1.7%.

Pharmaceutical firms traded higher, however, AstraZeneca rose 0.8% and GSK added 1.1%. Supporting the latter, Citi lifted the stock 'buy', its first positive rating on the shares in seven years.

Tui shares rose 1.7%. Tui's pretax loss narrowed to EUR103.1 million in the first quarter that ended December 31 from EUR272.6 million a year before, as revenue rose by 15% to a "record" EUR4.30 billion from EUR3.75 billion.

Underlying earnings before interest and tax were EUR6.0 million, swung from a EUR153.0 million Ebit loss a year before.

Edison analyst Russell Pointon commented: "Tui has unveiled its Q1 2024 results, showcasing a record-breaking performance.

"However, among the positive financial results, Tui's shareholders are poised to vote on the company's plans to delist from the London Stock Exchange, a move supported by the board but subject to shareholder approval at today's upcoming AGM. With market attention poised to quickly shift from Tui's results to its listing status, all eyes are on this pivotal moment in the company's trajectory."

Brent oil was quoted at USD82.55 a barrel midday Tuesday, rising from USD81.69 late Monday. Gold rose to USD2,027.59 an ounce from USD2,013.55.

By Eric Cunha, Alliance News news editor

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
Today 09:44

AstraZeneca says withdraws Covid vaccine "for commercial reasons"

(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemic, citing "commercial reasons" and a surplus of updated jabs.

Read more
Today 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
7 May 2024 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.